

## Datasheet: AAI22P

**BATCH NUMBER 161920**

<b>Description:</b>	SHEEP ANTI BOVINE IgG2:HRP
<b>Specificity:</b>	IgG2
<b>Format:</b>	HRP
<b>Product Type:</b>	Polyclonal Antibody
<b>Isotype:</b>	Polyclonal IgG
<b>Quantity:</b>	1 mg

### Product Details

#### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
Immunohistology - Frozen			▪	
Immunohistology - Paraffin			▪	
ELISA	▪			1/10,000 - 1/100,000
Western Blotting			▪	

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using the appropriate negative/positive controls.

<b>Target Species</b>	Bovine
<b>Product Form</b>	Purified IgG conjugated to Horseradish Peroxidase (HRP) - liquid
<b>Antiserum Preparation</b>	Antisera to bovine IgG2 were raised by repeated immunisation of sheep with highly purified antigen. Purified IgG prepared by affinity chromatography.
<b>Buffer Solution</b>	Phosphate buffered saline
<b>Preservative Stabilisers</b>	0.05% Proclin™ 300
<b>Approx. Protein Concentrations</b>	IgG concentration 1.0 mg/ml
<b>Immunogen</b>	Purified bovine IgG2.

**Specificity**

**Sheep anti Bovine IgG2 polyclonal antibody** recognizes bovine IgG2.

No cross - reactivity with other bovine immunoglobulin classes is seen in immunoelectrophoresis. This product may cross-react with IgG2 from other species.

**References**

1. Makepeace, B.L. *et al.* (2009) Immunisation with a multivalent, subunit vaccine reduced patent infection in a natural bovine model of Onchocerciasis during intense field exposure. [PLoS Negl. Trop. Dis. 3: e544.](#)
2. Colwell, D.D. & Goater, C.P. (2010) *Dicrocoelium dendriticum* in cattle from Cypress Hills, Canada: humoral response and preliminary evaluation of an ELISA. [Vet Parasitol. 174 \(1-2\): 162-5.](#)
3. Assad, A. *et al.* (2012) Immunophenotyping and characterization of BNP colostrum revealed pathogenic alloantibodies of IgG1 subclass with specificity to platelets, granulocytes and monocytes of all maturation stages. [Vet Immunol Immunopathol. 147: 25-34.](#)
4. Agnes, J.T. *et al.* (2011) Identification of *Anaplasma marginale* Outer Membrane Protein Antigens Conserved between *A. marginale* Sensu Stricto Strains and the Live *A. marginale* subsp. centrale Vaccine [Infect Immun. 79: 1311-8.](#)
5. Lavoria, M.Á. *et al.* (2012) Avidity and subtyping of specific antibodies applied to the indirect assessment of heterologous protection against Foot-and-Mouth Disease Virus in cattle. [Vaccine. 30: 6845-50.](#)
6. Vordermeier, H.M. *et al.* (2003) Improved immunogenicity of DNA vaccination with mycobacterial HSP65 against bovine tuberculosis by protein boosting. [Vet Microbiol. 93: 349-59.](#)
7. Mansilla, F.C. *et al.* (2013) Dose-dependent immunogenicity of a soluble *Neospora caninum* tachyzoite-extract vaccine formulated with a soy lecithin/ $\beta$ -glucan adjuvant in cattle. [Vet Parasitol. 197 \(1-2\): 13-21.](#)
8. Panadero, R. *et al.* (2013) Effect of reinfestations on systemic immune responses in cattle naturally infested by *Hypoderma* sp. (Diptera: Oestridae). [Vet Parasitol. 193: 238-44.](#)
9. Ploegaert, T.C. *et al.* (2010) Genetic variation of natural antibodies in milk of Dutch Holstein-Friesian cows. [J Dairy Sci. 93: 5467-73.](#)
10. Van Meulder, F. *et al.* (2013) Granule exocytosis of granulysin and granzyme B as a potential key mechanism in vaccine-induced immunity in cattle against the nematode *Ostertagia ostertagi*. [Infect Immun. 81: 1798-809.](#)
11. Maree, F.F. *et al.* (2015) Intra-serotype SAT2 chimeric foot-and-mouth disease vaccine protects cattle against FMDV challenge. [Vaccine. 33 \(25\): 2909-16.](#)
12. Rybarczyk, J. *et al.* (2017) Effects of lactoferrin treatment on *Escherichia coli* O157:H7 rectal colonization in cattle. [Vet Microbiol. 202: 38-46.](#)
13. González-Hernández A *et al.* (2016) Host protective ASP-based vaccine against the parasitic nematode *Ostertagia ostertagi* triggers NK cell activation and mixed IgG1-IgG2 response. [Sci Rep. 6: 29496.](#)
14. Pecora, A. *et al.* (2015) Development of an APC-targeted multivalent E2-based vaccine against Bovine Viral Diarrhea Virus types 1 and 2. [Vaccine. 33 \(39\): 5163-71.](#)
15. Scott, K.A. *et al.* (2017) Evaluation of immune responses of stabilised SAT2 antigens

of foot-and-mouth disease in cattle. [Vaccine. 35 \(40\): 5426-33.](#)

16. Sheng, Z.A. *et al.* (2019) Th2-related cytokines are associated with *Fasciola gigantica* infection and evasion in the natural host, swamp buffalo. [Vet Parasitol. 268: 73-80.](#)

17. Bucafusco, D. *et al.* (2019) Immune cells transferred by colostrum do not influence the immune responses to foot-and-mouth disease primary vaccination. [J Dairy Sci. 102 \(9\): 8376-84.](#)

18. Jiménez-Pelayo, L. *et al.* (2019) Early *Neospora caninum* infection dynamics in cattle after inoculation at mid-gestation with high (Nc-Spain7)- or low (Nc-Spain1H)-virulence isolates. [Vet Res. 50 \(1\): 72.](#)

19. Rainard, P. *et al.* (2017) Cellular and humoral immune response to recombinant *Escherichia coli*. OmpA in cows. [PLoS One. 12 \(10\): e0187369.](#)

20. Springer, A. *et al.* (2022) Immunization Trials with Recombinant Major Sperm Protein of the Bovine Lungworm *Dictyocaulus viviparus*. [Pathogens 2022, 11, 55.](#)

---

<b>Storage</b>	Store at +4°C. DO NOT FREEZE. This product should be stored undiluted. Should this product contain a precipitate we recommend microcentrifugation before use.
<b>Guarantee</b>	12 months from date of despatch
<b>Acknowledgements</b>	Proclin™ 300 is a trademark of The Dow Chemical Company (“Dow”) or an affiliated company of Dow.
<b>Health And Safety Information</b>	Material Safety Datasheet documentation #20392 available at: <a href="https://www.bio-rad-antibodies.com/SDS/AAI22P20392">https://www.bio-rad-antibodies.com/SDS/AAI22P20392</a>
<b>Regulatory</b>	For research purposes only

---

## Related Products

### Recommended Useful Reagents

[AbGUARD® HRP STABILIZER PLUS \(BUF052A\)](#)

[AbGUARD® HRP STABILIZER PLUS \(BUF052B\)](#)

[AbGUARD® HRP STABILIZER PLUS \(BUF052C\)](#)

[TMB CORE \(BUF056A\)](#)

[TMB CORE+ \(BUF062A\)](#)

[TMB SIGNAL+ \(BUF054A\)](#)

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://bio-rad-antibodies.com/datasheets)

'M363607:200528'

Printed on 01 Mar 2024